Ulimorelin Study of Efficacy and Safety (ULISES 008)

Phase 3

Completed

• Conditions: Gastrointestinal Dysmotility
• Interventions: Drug: Ulimorelin Intravenously (IV); Drug: Ulimorelin Invtravenously (IV); Drug: 5% dextrose in water

• Registration Number: NCT01296620
• Lead Sponsor: Tranzyme, Inc.

Brief Summary

Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection

Detailed Description

Not available

Study Timeline

• Study Start: 2011-02
• Study First Submitted: 2011-02-14
• Study First Submitted QC: 2011-02-14
• Study First Posted: 2011-02-15
• Primary Completion: 2012-03
• Study Completion: 2012-03
• Status Verified: 2012-07
• Last Update Submitted: 2012-07-25
• Last Update Posted: 2012-07-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

• Men or women, 18 to 80 years of age, inclusive
• Scheduled to undergo open bowel resection with colonic anastomosis
• For women who can potentially become pregnant a pregnancy test at screening and admission must be negative

Exclusion Criteria

• Weight more than 200kg (441 pounds)
• Pregnant or breastfeeding
• Known history of drug or alcohol abuse within the previous year

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental 1	Ulimorelin Intravenously (IV)	-
Experimental 2	Ulimorelin Invtravenously (IV)	-
Placebo	5% dextrose in water	-

Primary Outcome Measures

Name	Time	Method
Recovery of GI Function	up to 7 days of dosing or until hospital discharge

Secondary Outcome Measures

Name	Time	Method
Ancillary GI Functions	up to 7 days of dosing or hospital discharge

Trial Locations

Locations (50)

Glendale Memorial Hospital; 🇺🇸 Glendale, California, United States

Long Beach Memorial Medical Center; 🇺🇸 Long Beach, California, United States

Univ. of Southern California; 🇺🇸 Los Angeles, California, United States

Cedars Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Palo Alto VA Health Care Ctr; 🇺🇸 Palo Alto, California, United States

Citrus Memorial Hospital; 🇺🇸 Inverness, Florida, United States

Pensacola Research Consultants; 🇺🇸 Pensacola, Florida, United States

Tampa General Hospital; 🇺🇸 Tampa, Florida, United States

ARS Clinical Trials; 🇺🇸 Powder Springs, Georgia, United States

University of Iowa Hospitals and Clinics; 🇺🇸 Iowa City, Iowa, United States

Scroll for more (40 remaining)